ESTRO 2024 - Abstract Book

S508

Clinical - Breast

ESTRO 2024

The mean excess absolute increase in lifetime risk of mortality due to IHD 0.72 % (SD 0.29%) in CONTROL vs 0.50 % (SD 0.25%) in the EXP arm (Wilcoxon rank sum p < 0.001). The average upper estimate of the absolute increase in mortality were 1.65% (SD 0.68%) in the CONTROL and 1.15% (SD 0.64%) in the EXP arm. Figure 1 shows the lifetime risk of mortality due to IHD within the trial population for each age group following in each arm along with the baseline risk without radiotherapy.

Made with FlippingBook - Online Brochure Maker